{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:14:59Z","timestamp":1791357299780,"version":"4.3.1"},"reference-count":320,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.schres.2010.05.025","type":"journal-article","created":{"date-parts":[[2010,7,24]],"date-time":"2010-07-24T10:49:34Z","timestamp":1279968574000},"page":"1-23","source":"Crossref","is-referenced-by-count":282,"title":["Schizophrenia, \u201cJust the Facts\u201d 5. Treatment and prevention Past, present, and future"],"prefix":"10.1016","volume":"122","author":[{"given":"Rajiv","family":"Tandon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry A.","family":"Nasrallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matcheri S.","family":"Keshavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2010.05.025_bib1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1192\/bjp.179.4.290","article-title":"Systematic meta-review of depot antipsychotic drugs for people with schizophrenia","volume":"179","author":"Adams","year":"2001","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib2","series-title":"The Cochrane Library","article-title":"Cochrane Schizophrenia Group publications","author":"Adams","year":"2009"},{"key":"10.1016\/j.schres.2010.05.025_bib3","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/archpsyc.60.12.1228","article-title":"Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected","volume":"60","author":"Agid","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib4","doi-asserted-by":"crossref","first-page":"416","DOI":"10.4088\/JCP.v68n0310","article-title":"Efficacy of slow repetitive transcranial magnetic stimulation in the treatment of resistant auditory hallucinations in schizophrenia: a meta-analysis","volume":"68","author":"Aleman","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib5","series-title":"Cochrane Database Systematic Reviews CD006329","article-title":"Cessation of medication for people with schizophrenia already on chlorpromazine","author":"Alkhateeb","year":"2007"},{"key":"10.1016\/j.schres.2010.05.025_bib6","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib7","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.pharmthera.2008.10.010","article-title":"Current status of inverse agonism at serotonin 2A and 2C receptors","volume":"121","author":"Aloyo","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.schres.2010.05.025_bib305","unstructured":"Alvarez-Jimenez, M., Parker, A.G., Hetrick, S.E., et al., in press. Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis. Schizophr. Bull. doi:10.1093\/schbul\/\/sbp129"},{"key":"10.1016\/j.schres.2010.05.025_bib8","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/archgenpsychiatry.2009.192","article-title":"Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial","volume":"67","author":"Amminger","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib306","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","article-title":"Remission in schizophrenia: proposed criteria and rationale for consensus","volume":"162","author":"Andreasen","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00787-005-0515-2","article-title":"Antipsychotics in early onset schizophrenia: systematic review and meta-analysis","volume":"15","author":"Armenteros","year":"2006","journal-title":"Eur. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0893-133X(97)00112-7","article-title":"Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence","volume":"18","author":"Arnt","year":"1998","journal-title":"Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2010.05.025_bib11","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/schbul\/sbn114","article-title":"Pharmacogenetics in psychiatry: are we ready for widespread clinical use?","volume":"34","author":"Arranz","year":"2008","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2010.05.025_bib12","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1586\/epr.09.85","article-title":"The audacity of proteomics: a challenge to overcome current challenges in schizophrenia research","volume":"6","author":"Baloyianni","year":"2009","journal-title":"Expert Rev. Proteomics"},{"key":"10.1016\/j.schres.2010.05.025_bib13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/schbul\/sbn163","article-title":"Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting","volume":"35","author":"Barch","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2010.05.025_bib14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.schres.2004.01.016","article-title":"Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials","volume":"70","author":"Basan","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2010.05.025_bib15","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1093\/hmg\/11.20.2517","article-title":"Pharmacogenomics in schizophrenia: the quest for individualized therapy","volume":"11","author":"Basile","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.schres.2010.05.025_bib16","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1037\/0022-006X.58.6.741","article-title":"Social skills training with schizophrenia: a meta-analytic evaluation","volume":"58","author":"Benton","year":"1990","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.schres.2010.05.025_bib17","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1177\/070674379704200303","article-title":"Neurocognitive impairment in schizophrenia and how it affects treatment options","volume":"42","author":"Bilder","year":"1997","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1192\/S0007125000297663","article-title":"Early intervention in psychosis. The critical period hypothesis","volume":"172","author":"Birchwood","year":"1998","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1472-8206.2009.00751.x","article-title":"Pharmacogenetics of response efficacy of antipsychotics in schizophrenia","volume":"24","author":"Blanc","year":"2010","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2010.05.025_bib20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/YCO.0b013e3283366657","article-title":"Repetitive transcranial magnetic stimulation for refractory symptoms in schizophrenia","volume":"23","author":"Blumberger","year":"2010","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib21","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1176\/ps.2008.59.7.782","article-title":"Indicators of conformance with guidelines of schizophrenia treatment in mental health services","volume":"59","author":"Bollini","year":"2008","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.schres.2010.05.025_bib22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/BF02519193","article-title":"Assertive outreach for frequent users of psychiatric hospitals: a meta-analysis","volume":"22","author":"Bond","year":"1995","journal-title":"J. Ment. Health Adm."},{"key":"10.1016\/j.schres.2010.05.025_bib23","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/01.pra.0000327312.04153.da","article-title":"Are second-generation antipsychotics a distinct class?","volume":"14","author":"Bonham","year":"2008","journal-title":"J. Psychiatr. Pract."},{"key":"10.1016\/j.schres.2010.05.025_bib24","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1038\/npp.2008.39","article-title":"Antipsychotic properties of 5-alpha-reductase inhibitors","volume":"33","author":"Bortolato","year":"2008","journal-title":"Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2010.05.025_bib25","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1017\/S0033291709990341","article-title":"Early intervention in psychotic disorders: faith before facts?","volume":"40","author":"Bosanac","year":"2010","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2010.05.025_bib26","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.neuropharm.2009.10.003","article-title":"AC-260584, an orally bioavailable M(1) receptor allosteric agonist, improves cognitive performance in an animal model","volume":"58","author":"Bradley","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.schres.2010.05.025_bib27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/01.yct.0000165500.60784.05","article-title":"The combined use of electroconvulsive therapy and antipsychotics in patients with schizophrenia","volume":"21","author":"Braga","year":"2005","journal-title":"J. ECT"},{"key":"10.1016\/j.schres.2010.05.025_bib28","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archpsyc.1991.01810270051007","article-title":"National Institute of Mental Health longitudinal study of chronic schizophrenia: prognosis and predictors of outcome","volume":"48","author":"Breier","year":"1991","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib29","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1124\/jpet.109.157388","article-title":"WS-50030: a novel dopamine D-2 receptor partial agonist\/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity","volume":"32","author":"Brennan","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.schres.2010.05.025_bib30","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1192\/bjp.121.3.241","article-title":"Influence of family life on the course of schizophrenic illness: a replication","volume":"121","author":"Brown","year":"1972","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib31","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements","volume":"36","author":"Buchanan","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2010.05.025_bib32","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1136\/bmj.39251.599259.55","article-title":"Use of intensive case management to reduce time in hospital in people with severe mental illness: systematic review and meta-regression","volume":"335","author":"Burns","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.schres.2010.05.025_bib33","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1176\/appi.ajp.158.2.163","article-title":"The psychosocial treatment of schizophrenia: an update","volume":"158","author":"Bustillo","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib34","article-title":"Who benefits from supported employment: A meta-analytic study","author":"Campbell","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2010.05.025_bib35","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/sj.npp.1301639","article-title":"The evolution of drug development in schizophrenia: past issues and future opportunities","volume":"33","author":"Carpenter","year":"2008","journal-title":"Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2010.05.025_bib308","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1176\/ajp.145.5.578","article-title":"Deficit and nondeficit forms of schizophrenia: the concept","volume":"145","author":"Carpenter","year":"1988","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib36","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1176\/ajp.117.2.97","article-title":"Treatment of schizophrenic patients with phenothiazine derivatives","volume":"116","author":"Casey","year":"1960","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib37","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1176\/appi.ajp.158.4.518","article-title":"Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials","volume":"158","author":"Chakos","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib38","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/YCT.0b013e3181a74368","article-title":"A survey of the practice of electroconvulsive therapy in Asia","volume":"26","author":"Chanpattana","year":"2010","journal-title":"J. ECT"},{"key":"10.1016\/j.schres.2010.05.025_bib39","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.neuropharm.2009.07.027","article-title":"GABAA receptors and their associated proteins: Implications in the etiology and treatment of schizophrenia and related disorders","volume":"57","author":"Charych","year":"2009","journal-title":"Neuropharmacol."},{"key":"10.1016\/j.schres.2010.05.025_bib40","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.IDT.0000360999.60168.a4","article-title":"First- and second-generation antipsychotics and the concept of \u201catypicality\u201d: implications for clinical practice","volume":"44","author":"Chen","year":"2009","journal-title":"Psychopharmacol. Rev."},{"key":"10.1016\/j.schres.2010.05.025_bib41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1192\/bjp.bp.105.008375","article-title":"Effects of a mutual support group for families of Chinese people with schizophrenia","volume":"189","author":"Chien","year":"2006","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib43","doi-asserted-by":"crossref","first-page":"122","DOI":"10.4088\/JCP.08m04315","article-title":"Comparing acute toxicity of first- and second-generation antipsychotic drugs: a 10-year, retrospective cohort study","volume":"70","author":"Ciranni","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib44","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1176\/ajp.2007.164.3.393","article-title":"The effectiveness of assertive community treatment for homeless populations with severe mental illness: a meta-analysis","volume":"164","author":"Coldwell","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib45","first-page":"14","article-title":"Evaluation of drug treatments in psychiatry","volume":"52","author":"Cole","year":"1964","journal-title":"Proc. Annu. Meet. Am. Psychopathol. Assoc."},{"key":"10.1016\/j.schres.2010.05.025_bib46","first-page":"11","article-title":"Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states","volume":"3","author":"Colton","year":"2006","journal-title":"Prev. Chron. Dis."},{"key":"10.1016\/j.schres.2010.05.025_bib47","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.amepre.2003.10.003","article-title":"Considering schizophrenia from a prevention perspective","volume":"26","author":"Compton","year":"2004","journal-title":"Am. J. Prev. Med."},{"key":"10.1016\/j.schres.2010.05.025_bib48","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.tips.2008.10.006","article-title":"Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia","volume":"30","author":"Conn","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.schres.2010.05.025_bib50","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4088\/JCP.v68n0410","article-title":"Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents","volume":"68","author":"Cornblatt","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib51","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1136\/bmj.322.7296.1207","article-title":"Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study","volume":"322","author":"Coulter","year":"2001","journal-title":"Br. Med. J."},{"key":"10.1016\/j.schres.2010.05.025_bib52","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1126\/science.3854","article-title":"Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs","volume":"192","author":"Creese","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.schres.2010.05.025_bib53","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/0957154X07070335","article-title":"The history of clozapine and its emergence in the US market: a review and analysis","volume":"18","author":"Crilly","year":"2007","journal-title":"Hist. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib307","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1192\/bjp.bp.109.066217","article-title":"Efficacy of atypical V. typical antipsychotics in the treatment of early psychosis: meta-analysis","volume":"196","author":"Crossley","year":"2010","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib54","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10597-009-9228-1","article-title":"Oil and water or oil and vinegar? Evidence-based medicine meets vinegar","volume":"45","author":"Davidson","year":"2009","journal-title":"Community Ment. Health J."},{"key":"10.1016\/j.schres.2010.05.025_bib55","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1176\/appi.ajp.2008.08060806","article-title":"Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST)","volume":"166","author":"Davidson","year":"2009","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib56","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1037\/0033-2909.83.3.431","article-title":"Maintenance antipsychotic drugs do prevent relapse","volume":"83","author":"Davis","year":"1976","journal-title":"Psychol. Bull."},{"key":"10.1016\/j.schres.2010.05.025_bib57","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/schbul\/6.1.70","article-title":"Important issues in the drug treatment of schizophrenia","volume":"6","author":"Davis","year":"1980","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2010.05.025_bib58","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.60.6.553","article-title":"A meta-analysis of the efficacy of second-generation antipsychotics","volume":"60","author":"Davis","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib59","doi-asserted-by":"crossref","first-page":"344","DOI":"10.2174\/138161210790170067","article-title":"Therapeutic utility of NK3 receptor antagonists for the treatment of schizophrenia","volume":"16","author":"Dawson","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.schres.2010.05.025_bib60","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.eurpsy.2009.01.005","article-title":"Cardiovascular disease and diabetes in people with severe mental illness","volume":"24","author":"De Hert","year":"2009","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib61","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.schres.2009.12.029","article-title":"Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study","volume":"117","author":"De Hert","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2010.05.025_bib62","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1600-0447.2009.01372.x","article-title":"Early intervention in patients at ultra high risk of psychosis: benefits and risks","volume":"119","author":"De Koning","year":"2009","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2010.05.025_bib63","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.phrs.2008.10.002","article-title":"The future (or lack of future) of personalized prescription in psychiatry","volume":"59","author":"De Leon","year":"2009","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.schres.2010.05.025_bib64","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1176\/appi.psy.46.3.262","article-title":"The dosing of atypical antipsychotics","volume":"46","author":"De Leon","year":"2005","journal-title":"Psychosomatics"},{"key":"10.1016\/j.schres.2010.05.025_bib65","first-page":"267","article-title":"Traitement des etats d'excitation et d'agitation par une methode medicamenteuse derive de l'hibernotherapie","volume":"119","author":"Delay","year":"1952","journal-title":"Ann. Medicopsychol."},{"key":"10.1016\/j.schres.2010.05.025_bib66","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/JCP.0b013e3181d2193c","article-title":"Antipsychotic drug treatment in first-episode psychosis","volume":"30","author":"Derks","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2010.05.025_bib67","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/WNF.0b013e318067e255","article-title":"Epigenetic therapeutic strategies for the treatment of neuropsychiatric disorders: ready for prime time ?","volume":"31","author":"Deutch","year":"2008","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.schres.2010.05.025_bib325","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0022-3956(98)00024-7","article-title":"Do atypical antipsychotics favorably alter the long-term course of schizophrenia","volume":"32","author":"DeQuardo","year":"1998","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2010.05.025_bib68","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1176\/appi.ajp.2009.09020264","article-title":"A randomized, controlled trial of computer-assisted cognitive remediation for schizophrenia","volume":"167","author":"Dickinson","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib69","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/schbul\/sbp115","article-title":"The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements","volume":"36","author":"Dixon","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2010.05.025_bib70","doi-asserted-by":"crossref","first-page":"411","DOI":"10.4088\/JCP.08r04808yel","article-title":"Repetitive transcranial magnetic stimulation for negative and cognitive symptoms of schizophrenia: review and meta-analysis","volume":"71","author":"Dlabac-de Lange","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib71","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/schbul\/sbp041","article-title":"Implementing evidence-based practices for people with schizophrenia","volume":"35","author":"Drake","year":"2009","journal-title":"Schizophr. Bull."},{"issue":"42","key":"10.1016\/j.schres.2010.05.025_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta9420","article-title":"Long-term outcome of cognitive behavior therapy clinical trials in central Scotland","volume":"9","author":"Durham","year":"2005","journal-title":"Health Technol. Assess."},{"key":"10.1016\/j.schres.2010.05.025_bib73","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/schbul\/sbl071","article-title":"Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis","volume":"33","author":"Eack","year":"2007","journal-title":"Schizophr. Bull."},{"issue":"7","key":"10.1016\/j.schres.2010.05.025_bib309","article-title":"Neuroprotective effects of cognitive enhancement therapy in schizophrenia","volume":"67","author":"Eack","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib74","doi-asserted-by":"crossref","first-page":"11785","DOI":"10.1523\/JNEUROSCI.3798-08.2008","article-title":"Adult neurogenesis, mental health, and mental illness: hope or hype?","volume":"28","author":"Eisch","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.schres.2010.05.025_bib75","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/schbul\/sbn194","article-title":"Drug discovery in psychiatric illness: mining for gold","volume":"35","author":"Elmer","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2010.05.025_bib76","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1176\/ajp.2006.163.4.743","article-title":"Time course for antipsychotic treatment response in first-episode schizophrenia","volume":"163","author":"Emsley","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib77","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/15622970510030090","article-title":"World Federation of Societies of Biological Psychiatry guidelines for biological treatment of schizophrenia, part 1: acute treatment","volume":"6","author":"Falkai","year":"2005","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib78","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1358\/dot.2009.045.004.1353924","article-title":"Potential microbial origins of schizophrenia and their treatments","volume":"45","author":"Fatemi","year":"2009","journal-title":"Drugs Today"},{"key":"10.1016\/j.schres.2010.05.025_bib79","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000135641","article-title":"Typical and atypical antipsychotics \u2014 the misleading dichotomy","volume":"57","author":"Fischer-Barnicol","year":"2008","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.schres.2010.05.025_bib80","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1176\/appi.ajp.2009.08050757","article-title":"Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia","volume":"166","author":"Fisher","year":"2009","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib81","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1176\/appi.ajp.162.2.370","article-title":"Prevalence and risk factors for homelessness and utilization of mental health services among 10, 340 patients with severe mental illness in a large public mental health system","volume":"162","author":"Folsom","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib82","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.schres.2008.11.027","article-title":"Meta-analysis of the effects of repetitive transcranial magnetic stimulation (rTMS) on negative and positive symptoms in schizophrenia","volume":"108","author":"Freitas","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2010.05.025_bib83","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1176\/appi.ajp.2009.08121873","article-title":"Roles of the Akt\/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action","volume":"167","author":"Freyberg","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib84","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2007.06.016","article-title":"Revisiting the relapse predictive validity of prodromal symptoms in schizophrenia","volume":"95","author":"Gaebel","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2010.05.025_bib310","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","article-title":"International consensus study of antipsychotic dosing","volume":"167","author":"Gardner","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib85","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/BF00414036","article-title":"The importance of dosage in antipsychotic drug administration: a review of dose\u2013response studies","volume":"29","author":"Gardos","year":"1973","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2010.05.025_bib86","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1192\/bjp.bp.107.043570","article-title":"Cognitive\u2013behavioral therapy and family intervention for relapse prevention and symptom reduction in psychosis: randomized controlled trial","volume":"192","author":"Garety","year":"2008","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib87","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.2174\/138945006778226543","article-title":"Evolution of antipsychotic intervention in schizophrenia","volume":"7","author":"Garver","year":"2006","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.schres.2010.05.025_bib88","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/j.1471-4159.2009.06325.x","article-title":"Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications","volume":"111","author":"Gaspar","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.schres.2010.05.025_bib89","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1136\/bmj.321.7273.1371","article-title":"Atypical antipsychotics in the treatment of schizophrenia: >>systematic overview and meta-regression analysis","volume":"231","author":"Geddes","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.schres.2010.05.025_bib90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euroneuro.2008.07.002","article-title":"BL-1020: a novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia","volume":"19","author":"Geffen","year":"2009","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2010.05.025_bib91","doi-asserted-by":"crossref","first-page":"363","DOI":"10.31887\/DCNS.2009.11.4\/pgerretsen","article-title":"The intersection of pharmacology, imaging, and genetics in the development of personalized medicine","volume":"11","author":"Gerretsen","year":"2009","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.schres.2010.05.025_bib92","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/archpsyc.1995.03950150005001","article-title":"Neuroleptic withdrawal in schizophrenic patients. A review of the literature","volume":"52","author":"Gilbert","year":"1995","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib93","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1017\/S0033291709006126","article-title":"Efficacy and effectiveness of individual family intervention on social and clinical functioning and family burden in severe schizophrenia: a 2-year randomized controlled study","volume":"40","author":"Giron","year":"2010","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2010.05.025_bib94","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1176\/appi.ajp.158.11.1774","article-title":"Antipsychotic drugs: prolonged QTc interval, torsade de pointes and sudden death","volume":"158","author":"Glassman","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib95","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/archpsyc.64.10.1115","article-title":"Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?","volume":"64","author":"Goldberg","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib97","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0920-9964(00)00145-6","article-title":"Cognitive therapy for schizophrenia: an effect size analysis","volume":"48","author":"Gould","year":"2001","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2010.05.025_bib98","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0166-2236(96)10064-3","article-title":"Dopamine-cell depolarization block as a model for the therapeutic action of antipsychotic drugs","volume":"20","author":"Grace","year":"1997","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.schres.2010.05.025_bib99","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1124\/jpet.109.155994","article-title":"Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative, symptoms of schizophrenia","volume":"331","author":"Grauer","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.schres.2010.05.025_bib100","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1124\/mol.109.061333","article-title":"Is there a role for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders?","volume":"77","author":"Grayson","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.schres.2010.05.025_bib101","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1176\/ajp.153.3.321","article-title":"What are the functional consequences of neurocognitive deficits in schizophrenia?","volume":"153","author":"Green","year":"1996","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib102","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S0006-3223(00)01027-1","article-title":"Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications","volume":"49","author":"Green","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta9090","article-title":"Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia, and mania: systematic reviews and economic modeling studies","volume":"9","author":"Greenhalgh","year":"2005","journal-title":"Health Technol. Assess."},{"key":"10.1016\/j.schres.2010.05.025_bib104","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrd2806","article-title":"The \u2018atypicality\u2019 of antipsychotics: a concept re-examined and re-defined","volume":"8","author":"Grunder","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.schres.2010.05.025_bib105","series-title":"The Action of Neuroleptic Drugs","author":"Haase","year":"1965"},{"key":"10.1016\/j.schres.2010.05.025_bib106","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antipsychotic-induced hyperprolactinemia: mechanisms, clinical features and management","volume":"64","author":"Haddad","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.schres.2010.05.025_bib107","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s11065-009-9103-4","article-title":"Pharmacological cognitive enhancement in schizophrenia","volume":"19","author":"Harvey","year":"2009","journal-title":"Neuropsychol. Rev."},{"key":"10.1016\/j.schres.2010.05.025_bib108","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/schbul\/sbn171","article-title":"Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept?","volume":"35","author":"Harvey","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2010.05.025_bib109","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1176\/appi.ajp.158.2.176","article-title":"Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment","volume":"158","author":"Harvey","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib110","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/156802610790410983","article-title":"Neuronal nicotinic acetylcholine receptors \u2014 targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer's disease","volume":"10","author":"Haydar","year":"2010","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.schres.2010.05.025_bib111","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/ern.09.143","article-title":"Effect of second-generation antipsychotics on cognition: current issues and future challenges","volume":"10","author":"Hill","year":"2010","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.schres.2010.05.025_bib112","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.1986.01800070019003","article-title":"Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia","volume":"43","author":"Hogarty","year":"1986","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib113","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1176\/ajp.154.11.1504","article-title":"Three year trials of personal therapy among schizophrenic patients living with or independent of family, I: description of study and effects on relapse rates","volume":"154","author":"Hogarty","year":"1997","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib114","series-title":"The Phenothiazines and Structurally Related Drugs","first-page":"667","article-title":"Clinical differences among phenothiazines in schizophrenics","author":"Hollister","year":"1974"},{"key":"10.1016\/j.schres.2010.05.025_bib115","doi-asserted-by":"crossref","first-page":"897","DOI":"10.4088\/JCP.v67n0606","article-title":"Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses","volume":"67","author":"Hugenholtz","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib116","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nrd2939","article-title":"Novel consortium to address shortfall in innovative medicines for psychiatric disorders","volume":"8","author":"Hughes","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.schres.2010.05.025_bib117","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/archgenpsychiatry.2008.540","article-title":"Translating scientific opportunity into public health impact: a strategic plan for research in mental illness","volume":"66","author":"Insel","year":"2009","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib118","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00702-009-0323-9","article-title":"The dopamine D(2) receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with L-dopa","volume":"117","author":"Jackson","year":"2010","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.schres.2010.05.025_bib119","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.schres.2010.02.002","article-title":"Time course of antipsychotic treatment response in schizophrenia: Results from a naturalistic study in 280 patients","volume":"118","author":"Jager","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2010.05.025_bib311","first-page":"468","article-title":"Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification","volume":"12","author":"Javitt","year":"2009","journal-title":"Curr. Opin.Drug Discov. Develop."},{"key":"10.1016\/j.schres.2010.05.025_bib120","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-244X-8-31","article-title":"Effectiveness of second generation antipsychotics: a systematic review of randomized trials","volume":"8","author":"Johnsen","year":"2008","journal-title":"BMC Psychiatry"},{"issue":"8069","key":"10.1016\/j.schres.2010.05.025_bib121","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S0140-6736(78)90193-9","article-title":"Mechanism of antipsychotic effect in the treatment of acute schizophrenia","volume":"1","author":"Johnstone","year":"1978","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2010.05.025_bib122","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","article-title":"Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia","volume":"63","author":"Jones","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib123","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2010.05.025_bib124","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1176\/ajp.2006.163.8.1316","article-title":"Tardive dyskinesia circa 2006","volume":"163","author":"Kane","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib125","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"issue":"Suppl. 12","key":"10.1016\/j.schres.2010.05.025_bib126","first-page":"5","article-title":"Expert consensus guideline series. Optimizing pharmacological treatment of psychotic disorders. Introduction, methods, commentary, and summary","volume":"64","author":"Kane","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib127","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/157488910789753512","article-title":"Recent patents on positive allosteric modulators of the metabotropic glutamate 5 receptor as a potential treatment for schizophrenia","volume":"5","author":"Kanuma","year":"2010","journal-title":"Recent Pat. CNS Drug Discov."},{"key":"10.1016\/j.schres.2010.05.025_bib128","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0006-3223(01)01251-3","article-title":"Dopamine D2 receptors and their role in antipsychotic action: still necessary and may even be sufficient","volume":"50","author":"Kapur","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib129","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D(2) occupancy, clinical response, and side-effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib130","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.schres.2005.01.003","article-title":"From dopamine to salience to psychosis-linking biology, pharmacology, and pharmacology of psychosis","volume":"79","author":"Kapur","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2010.05.025_bib131","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":"Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial","volume":"64","author":"Keefe","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib132","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/schbul\/sbn177","article-title":"Psychosocial treatments to promote functional recovery in schizophrenia","volume":"35","author":"Kern","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2010.05.025_bib133","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.schres.2008.07.020","article-title":"Schizophrenia, \u201cJust the Facts\u201d. What we know in 2008. Part 3: pathophysiology","volume":"106","author":"Keshavan","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2010.05.025_bib134","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.nurt.2008.10.020","article-title":"Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia","volume":"6","author":"Kim","year":"2009","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.schres.2010.05.025_bib135","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1017\/S0033291709990201","article-title":"Over-simplification and exclusion of non-conforming studies can demonstrate absence of effect: a lynching party","volume":"40","author":"Kingdon","year":"2010","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2010.05.025_bib136","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2165\/00023210-200418090-00005","article-title":"Dose response and atypical antipsychotics in schizophrenia","volume":"18","author":"Kinon","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2010.05.025_bib137","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/npp.2009.164","article-title":"Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia","volume":"35","author":"Kinon","year":"2010","journal-title":"Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2010.05.025_bib138","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/schbul\/sbj053","article-title":"The NIMH-MATRICS consensus statement on negative symptoms","volume":"32","author":"Kirkpatrick","year":"2006","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2010.05.025_bib139","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1124\/jpet.109.160432","article-title":"Cariprazine (RGH-188), a dopamine D3 receptor preferring D3\/D2 dopamine receptor antagonist\u2013partial agonist antipsychotic candidate: in vitro and neurochemical profile","volume":"333","author":"Kiss","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.schres.2010.05.025_bib140","doi-asserted-by":"crossref","first-page":"s29","DOI":"10.1192\/bjp.191.50.s29","article-title":"Outcomes of public concern in schizophrenia","volume":"191","author":"Kooyman","year":"2007","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib312","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/cmdc.201000186","article-title":"HTS and rational drug design to generate a new class of 5-HT2C-selective ligands for possible use in schizophrenia.","volume":"5","author":"Kozikowski","year":"2010","journal-title":"Chem. Med. Chem."},{"key":"10.1016\/j.schres.2010.05.025_bib141","first-page":"756","article-title":"Meta-analyses of randomized controlled trials of social skills training and cognitive remediation","volume":"33","author":"Krabbendam","year":"2003","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2010.05.025_bib142","unstructured":"Kraepelin E. Dementia Praecox and Paraphrenia, 1919, edited by Robertson GM), Krieger, New York, 1971."},{"key":"10.1016\/j.schres.2010.05.025_bib143","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.drudis.2009.05.002","article-title":"Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia","volume":"14","author":"Krystal","year":"2009","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.schres.2010.05.025_bib144","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1037\/0022-006X.76.3.491","article-title":"A meta-analysis of controlled research on social skills training for schizophrenia","volume":"76","author":"Kurtz","year":"2008","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.schres.2010.05.025_bib145","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.neubiorev.2009.08.002","article-title":"The involvement of the NMDA receptor d-serine\/glycine site in the pathophysiology and treatment of schizophrenia","volume":"34","author":"Labrie","year":"2010","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.schres.2010.05.025_bib146","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1055\/s-0029-1234105","article-title":"Early- and delayed-antipsychotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulpride","volume":"42","author":"Lambert","year":"2010","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib147","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/npp.2009.194","article-title":"Molecular mechanism of action and in vivo validation of an M4 muscarinic receptor allosteric modulator with potential antipsychotic properties","volume":"35","author":"Leach","year":"2010","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.schres.2010.05.025_bib148","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/00005053-199302000-00003","article-title":"Rehabilitation for adults with severe mental illness and substance use disorders: a clinical trial","volume":"181","author":"Lehman","year":"1993","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.schres.2010.05.025_bib149","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archpsyc.59.2.165","article-title":"Improving employment outcomes for persons with severe mental illnesses","volume":"59","author":"Lehman","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib150","first-page":"1","article-title":"Practice guidelines for the treatment of patients with schizophrenia","volume":"161","author":"Lehman","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib314","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ejphar.2009.12.043","article-title":"Metabotropic glutamate mGlu1 receptor stimulation and blockade: Therapeutic opportunities in psychiatric illness","volume":"639","author":"Lesage","year":"2010","journal-title":"Eur. J. Pharmacology"},{"key":"10.1016\/j.schres.2010.05.025_bib151","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0920-9964(98)00105-4","article-title":"Efficacy and extra-pyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials","volume":"35","author":"Leucht","year":"1999","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2010.05.025_bib152","doi-asserted-by":"crossref","first-page":"218","DOI":"10.4088\/JCP.v63n0308","article-title":"Carbamazepine augmentation for schizophrenia: how good is the evidence?","volume":"63","author":"Leucht","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib153","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1176\/appi.ajp.160.7.1209","article-title":"Relapse prevention in schizophrenia with new-generation antipsychotics. A systematic review and exploratory meta-analysis of randomized, controlled trials","volume":"160","author":"Leucht","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib154","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4088\/JCP.v65n0206","article-title":"Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials","volume":"65","author":"Leucht","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib155","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.biopsych.2005.02.023","article-title":"Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended","volume":"57","author":"Leucht","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib156","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/sj.mp.4002136","article-title":"How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials","volume":"14","author":"Leucht","year":"2009","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib157","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2010.05.025_bib158","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia","volume":"166","author":"Leucht","year":"2009","journal-title":"Am. J. Psychiatry"},{"issue":"Suppl. 435","key":"10.1016\/j.schres.2010.05.025_bib159","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1600-0447.2007.01084.x","article-title":"Clinical decision-making during 5years of antipsychotic treatment","volume":"116","author":"Levander","year":"2007","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2010.05.025_bib160","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/schbul\/sbn120","article-title":"Trajectories and antecedents of treatment response over time in early-episode psychosis","volume":"36","author":"Levine","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2010.05.025_bib161","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4088\/JCP.08m04666yel","article-title":"A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia","volume":"71","author":"Levkovitz","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib162","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/sj.npp.1301563","article-title":"Neuroplasticity of neocortical circuits in schizophrenia","volume":"33","author":"Lewis","year":"2008","journal-title":"Neuropsychopharmacol. Rev."},{"key":"10.1016\/j.schres.2010.05.025_bib163","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1172\/JCI37335","article-title":"Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies","volume":"119","author":"Lewis","year":"2009","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.schres.2010.05.025_bib164","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/schbul\/sbj067","article-title":"Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia","volume":"32","author":"Lewis","year":"2006","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2010.05.025_bib165","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/archpsyc.1993.01820170047006","article-title":"Time course and biologic correlates of treatment response in first-episode schizophrenia","volume":"50","author":"Lieberman","year":"1993","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib166","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J. Med."},{"key":"10.1016\/j.schres.2010.05.025_bib167","doi-asserted-by":"crossref","first-page":"983","DOI":"10.4088\/JCP.v67n0616","article-title":"Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection","volume":"67","author":"Lieberman","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib313","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/npp.2008.200","article-title":"A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia","volume":"34","author":"Lieberman","year":"2009","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.schres.2010.05.025_bib168","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.schres.2007.07.022","article-title":"Effectiveness of psychoeducation for relapse, symptoms, knowledge, adherence, and functioning in psychotic disorders: a meta-analysis","volume":"96","author":"Lincoln","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2010.05.025_bib169","series-title":"Cochrane Database Syst. Rev. CD007778.","article-title":"Chlorpromazine dose for people with schizophrenia","author":"Liu","year":"2009"},{"key":"10.1016\/j.schres.2010.05.025_bib170","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1176\/ajp.149.9.1183","article-title":"Duration of psychosis and outcome in first-episode schizophrenia","volume":"149","author":"Loebel","year":"1992","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib171","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1017\/S003329170900590X","article-title":"Cognitive behavior therapy for major psychiatric disorder: does it really work? A meta-analytical review of well-controlled trials","volume":"40","author":"Lynch","year":"2010","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2010.05.025_bib172","series-title":"Cochrane Database of Systematic Reviews CD001360","article-title":"Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illness","author":"Malmberg","year":"2009"},{"key":"10.1016\/j.schres.2010.05.025_bib173","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.schres.2004.09.010","article-title":"Measurement and treatment research to improve cognition in schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia","volume":"72","author":"Marder","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2010.05.025_bib174","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1176\/appi.ajp.161.8.1334","article-title":"Physical health monitoring of patients with schizophrenia","volume":"161","author":"Marder","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib175","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1017\/S0033291700027720","article-title":"An overview of family intervention and relapse on schizophrenia: meta-analysis of research findings","volume":"24","author":"Mari","year":"1994","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2010.05.025_bib176","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1021\/jm701094q","article-title":"Emerging opportunities for antipsychotic drug discovery in the postgenomic era","volume":"51","author":"Marino","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.schres.2010.05.025_bib177","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/npp.2008.173","article-title":"Removing obstacles in neuroscience drug discovery: the future path of animal models","volume":"34","author":"Markou","year":"2009","journal-title":"Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2010.05.025_bib178","series-title":"Cochrane Database of Systematic Reviews CD001089","article-title":"Assertive community treatment for persons with severe mental disorders","author":"Marshall","year":"1998"},{"key":"10.1016\/j.schres.2010.05.025_bib179","series-title":"Cochrane Database of Systematic Reviews CD004718","article-title":"Early intervention for psychosis","author":"Marshall","year":"2006"},{"key":"10.1016\/j.schres.2010.05.025_bib180","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00127-004-0762-4","article-title":"Schizophrenia and employment \u2014 a review","volume":"39","author":"Marwaha","year":"2004","journal-title":"Soc. Psychiatry Psychiatr. Epidemiol."},{"key":"10.1016\/j.schres.2010.05.025_bib181","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.schres.2010.01.002","article-title":"Quality assessment and comparison of evidence for electroconvulsive therapy and repetitive transcranial stimulation for schizophrenia: A systematic meta-review","volume":"118","author":"Matheson","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2010.05.025_bib182","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00003088-200746050-00001","article-title":"Clinical pharmacokinetics of typical antipsychotics","volume":"46","author":"Mauri","year":"2007","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.schres.2010.05.025_bib183","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0165-1781(92)90106-D","article-title":"Drug-responsive symptoms during early neuroleptic treatment","volume":"41","author":"Mazure","year":"1992","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2010.05.025_bib184","doi-asserted-by":"crossref","first-page":"516","DOI":"10.2174\/138161210790361470","article-title":"Antipsychotic medication: the potential role of 5HT1A receptor agonism","volume":"16","author":"McCreary","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.schres.2010.05.025_bib185","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior antipsychotic treatment","volume":"163","author":"McEvoy","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib186","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1001\/archpsyc.1995.03950200069016","article-title":"Multiple family groups and psychoeducation in the treatment of schizophrenia","volume":"52","author":"McFarlane","year":"1995","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib187","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1176\/ajp.2006.163.5.790","article-title":"Randomized double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis","volume":"163","author":"McGlashan","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib189","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/archpsyc.59.10.921","article-title":"Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms","volume":"59","author":"McGorry","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib190","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.4088\/JCP.08r04472","article-title":"Intervention in individuals at ultra high risk for psychosis: a review and future directions","volume":"70","author":"McGorry","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib315","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1600-0447.2010.01551.x","article-title":"Is it time to trial vitamin D supplements for the prevention of schizophrenia?","volume":"121","author":"McGrath","year":"2010","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2010.05.025_bib191","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1176\/appi.ajp.2007.07060906","article-title":"A meta-analysis of cognitive remediation in schizophrenia","volume":"164","author":"McGurk","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib316","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s11065-009-9097-y","article-title":"Cognitive remediation in schizophrenia","volume":"19","author":"Medalia","year":"2009","journal-title":"Neuropsychol. Rev."},{"key":"10.1016\/j.schres.2010.05.025_bib192","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(25)20710-8","article-title":"Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2, and serotonin2 pKi values","volume":"251","author":"Meltzer","year":"1989","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.schres.2010.05.025_bib193","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/archpsyc.60.1.82","article-title":"Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT)","volume":"60","author":"Meltzer","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib194","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/npp.2009.176","article-title":"Pimavanserin, a serotonin 2A receptor inverse agonist, for the treatment of Parkinson's disease psychosis","volume":"35","author":"Meltzer","year":"2010","journal-title":"Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2010.05.025_bib195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2004.01.014","article-title":"The effects of antipsychotic therapy on serum lipids: a comprehensive review","volume":"70","author":"Meyer","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2010.05.025_bib196","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1517\/13543780903286388","article-title":"Lurasidone: a new drug in development for schizophrenia","volume":"18","author":"Meyer","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.schres.2010.05.025_bib197","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1159\/000225979","article-title":"The hippocampus and nucleus accumbens as potential therapeutic targets for neurosurgical intervention in schizophrenia","volume":"87","author":"Mikell","year":"2009","journal-title":"Stereotact. Funct. Neurosurg."},{"key":"10.1016\/j.schres.2010.05.025_bib198","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.drudis.2009.12.004","article-title":"Use of biomarkers in the discovery of novel antischizophrenia drugs","volume":"15","author":"Mikkelsen","year":"2010","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.schres.2010.05.025_bib199","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.biopsych.2004.01.027","article-title":"A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book","volume":"55","author":"Mishara","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib200","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/01.pra.0000341889.97759.54","article-title":"Shared decision-making in antipsychotic management","volume":"14","author":"Mistler","year":"2008","journal-title":"J. Psychiatr. Pract."},{"key":"10.1016\/j.schres.2010.05.025_bib201","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs","volume":"10","author":"Miyamoto","year":"2005","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib202","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/oxfordjournals.schbul.a007047","article-title":"The concept of population prevention: application to schizophrenia","volume":"29","author":"Mojtabai","year":"2003","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2010.05.025_bib203","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/schbul\/sbp045","article-title":"Unmet need for mental health care in schizophrenia: an overview of literature and new data from a first-admission study","volume":"35","author":"Mojtabai","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2010.05.025_bib204","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2174\/187152710791012062","article-title":"Treating schizophrenia: novel targets for the cholinergic system","volume":"9","author":"Money","year":"2010","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.schres.2010.05.025_bib318","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1192\/bjp.185.4.291","article-title":"Cognitive therapy for the prevention of psychosis in people at ultra-high risk","volume":"185","author":"Morrison","year":"2004","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib205","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0091-3057(96)00425-X","article-title":"Cognitive function in schizophrenia \u2014 do neuroleptics make a difference?","volume":"56","author":"Mortimer","year":"1997","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.schres.2010.05.025_bib206","series-title":"Reducing risks for mental disorders: frontiers for preventive intervention research","author":"Mrazek","year":"1994"},{"key":"10.1016\/j.schres.2010.05.025_bib207","first-page":"31","article-title":"COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence","volume":"11","author":"Muller","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.schres.2010.05.025_bib208","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1600-0447.2006.00982.x","article-title":"The case for long-acting antipsychotic agents in the post-CATIE era","volume":"115","author":"Nasrallah","year":"2007","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2010.05.025_bib209","series-title":"American Psychiatric Press Textbook of Psychopharmacology","first-page":"533","article-title":"Classic antipsychotic medications","author":"Nasrallah","year":"2009"},{"key":"10.1016\/j.schres.2010.05.025_bib210","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1176\/appi.ps.56.3.273","article-title":"Defining and measuring clinical effectiveness in the treatment of schizophrenia","volume":"56","author":"Nasrallah","year":"2005","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.schres.2010.05.025_bib211","series-title":"Preventing mental, emotional, and behavioral disorders among young people: progress and possibilities","author":"National Research Council and Institute of Medicine","year":"2009"},{"key":"10.1016\/j.schres.2010.05.025_bib212","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1037\/0002-9432.77.3.350","article-title":"A review of the literature on the effectiveness of housing and support, assertive community treatment, and intensive case management interventions for persons with mental illness who have been homeless","volume":"77","author":"Nelson","year":"2007","journal-title":"Am. J. Orthopsychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib320","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.bmc.2010.01.040","article-title":"Searching for multi-target antipsychotics: Discovery of orally active heterocyclic N-phenylpiperazine ligands of D@-like and 5-HT1A receptors","volume":"18","author":"Neves","year":"2010","journal-title":"Bioorganic and Medicinal Chemistry"},{"key":"10.1016\/j.schres.2010.05.025_bib213","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/070674370605100803","article-title":"The metabolic effects of antipsychotic medications","volume":"51","author":"Newcomer","year":"2006","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib214","series-title":"Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care (update)","author":"NICE","year":"2009"},{"key":"10.1016\/j.schres.2010.05.025_bib215","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/JCP.0b013e31819a91f1","article-title":"Systematic review of Cochrane reviews for anticholinergic effects of antipsychotic drugs","volume":"29","author":"Ozbilen","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2010.05.025_bib216","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00124509-200603000-00013","article-title":"Combined use of electroconvulsive therapy and antipsychotics in schizophrenia: the Indian evidence. A review and a meta-analysis","volume":"22","author":"Painuly","year":"2006","journal-title":"J. ECT"},{"key":"10.1016\/j.schres.2010.05.025_bib217","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/nm1632","article-title":"Activation of mGlu2\/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial","volume":"13","author":"Patil","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.schres.2010.05.025_bib218","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.schres.2007.12.468","article-title":"Adjunctive psychosocial therapies for the treatment of schizophrenia","volume":"100","author":"Patterson","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2010.05.025_bib219","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1176\/appi.ajp.162.12.2220","article-title":"Psychosocial treatment for first-episode psychosis: a research update","volume":"162","author":"Penn","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib220","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1176\/appi.ajp.162.10.1785","article-title":"Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis","volume":"162","author":"Perkins","year":"2005","journal-title":"Am. J. Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.schres.2010.05.025_bib221","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1093\/schbul\/sbl030","article-title":"Efficacy of psychological therapy in schizophrenia: conclusions from meta-analyses","volume":"32","author":"Pfammatter","year":"2006","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2010.05.025_bib222","series-title":"Cochrane Database of Systematic Reviews CD000088","article-title":"Family intervention for schizophrenia","author":"Pharaoh","year":"2006"},{"key":"10.1016\/j.schres.2010.05.025_bib223","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1017\/S0033291702005895","article-title":"Psychological treatments in schizophrenia: I. Meta-analysis of family intervention and cognitive behavior therapy","volume":"32","author":"Pilling","year":"2002","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2010.05.025_bib224","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1017\/S0033291702005640","article-title":"Psychological treatments in schizophrenia: II. Meta-analysis of randomized controlled trials of social skills training and cognitive remediation","volume":"32","author":"Pilling","year":"2002","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2010.05.025_bib225","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/oxfordjournals.schbul.a006861","article-title":"The effect of family interventions on relapse and rehospitalization in schizophrenia: a meta-analysis","volume":"27","author":"Pitschel-Walz","year":"2001","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2010.05.025_bib226","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1124\/jpet.110.166710","article-title":"Behavioral indices in antipsychotic drug discovery.","volume":"333","author":"Porsolt","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.schres.2010.05.025_bib227","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/sj.mp.4001924","article-title":"Towards a muscarinic hypothesis of schizophrenia","volume":"12","author":"Raedler","year":"2007","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib228","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa0806994","article-title":"Atypical antipsychotic drugs and the risk of sudden cardiac death","volume":"360","author":"Ray","year":"2009","journal-title":"N. Eng. J. Med."},{"key":"10.1016\/j.schres.2010.05.025_bib229","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/00005053-200105000-00002","article-title":"Cognitive behavioral therapy for schizophrenia: an empirical review","volume":"189","author":"Rector","year":"2001","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.schres.2010.05.025_bib230","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2165\/11530250-000000000-00000","article-title":"Progress in defining optimal treatment outcome in schizophrenia","volume":"24","author":"Remington","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2010.05.025_bib231","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1192\/bjp.bp.108.055301","article-title":"Differences in mortality and suicidal behavior between treated and never-treated people with schizophrenia in rural China","volume":"195","author":"Ren","year":"2009","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib232","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.drudis.2007.07.018","article-title":"The impact of pharmacogenetics on the development and use of antipsychotic drugs","volume":"12","author":"Reynolds","year":"2007","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.schres.2010.05.025_bib317","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1755-5949.2009.00118.x","article-title":"Pregnelenone, dehydroepiandrosterone, and schizophrenia: Alterations and clinical trials","volume":"16","author":"Ritsner","year":"2010","journal-title":"CNS Neuroscience and Therapeutics"},{"key":"10.1016\/j.schres.2010.05.025_bib233","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1176\/ajp.156.4.544","article-title":"Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder","volume":"156","author":"Robinson","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib234","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1586\/14737175.9.1.47","article-title":"Treatment of schizophrenia in the 21st century: beyond the neurotransmitter hypothesis","volume":"9","author":"Rogers","year":"2009","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.schres.2010.05.025_bib235","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3109\/15622970801908047","article-title":"Potential antipsychotic properties of central canabinoid (CB1) receptor antagonists","volume":"11","author":"Roser","year":"2010","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib236","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2174\/156802610790411036","article-title":"5-HT6 receptor antagonists as potential therapeutics for cognitive impairment","volume":"10","author":"Rosse","year":"2010","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.schres.2010.05.025_bib319","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.biopsych.2009.07.008","article-title":"Tolcapone effects on gating working memory and mood interact with the synonymous catechol-O-methyltransferase rs4818 c\/g polymorphism","volume":"66","author":"Roussos","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib238","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/YCO.0b013e328324b687","article-title":"Intervention in the at-risk state to prevent transition to psychosis","volume":"22","author":"Ruhrmann","year":"2009","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib239","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/archpsyc.64.10.1123","article-title":"A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time","volume":"64","author":"Saha","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib240","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1176\/ajp.93.4.829","article-title":"New treatment for schizophrenia","volume":"93","author":"Sakel","year":"1937","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib241","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2165\/11314280-000000000-00000","article-title":"Antipsychotic drugs for first-episode schizophrenia: a comparative review","volume":"23","author":"Salimi","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2010.05.025_bib242","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1080\/08039480801984008","article-title":"Early detection and intervention of psychosis: a review","volume":"62","author":"Salokangas","year":"2008","journal-title":"Nord. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib243","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1124\/jpet.107.132910","article-title":"Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia","volume":"325","author":"Schmidt","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.schres.2010.05.025_bib244","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/261717a0","article-title":"Antipsychotic drug doses and neuroleptic\/dopamine receptors","volume":"261","author":"Seeman","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.schres.2010.05.025_bib245","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1017\/S1461145705005961","article-title":"A meta-analysis of profile and time-course of symptom change in acute schizophrenia treated with atypical antipsychotics","volume":"9","author":"Sherwood","year":"2006","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2010.05.025_bib246","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1176\/appi.ajp.2008.08050756","article-title":"Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study","volume":"165","author":"Sikich","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib247","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2165\/0023210-200822120-00002","article-title":"The role of phosphodiesterases in schizophrenia: therapeutic implications","volume":"22","author":"Sluciak","year":"2008","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2010.05.025_bib248","series-title":"First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis","author":"Smith","year":"2008"},{"key":"10.1016\/j.schres.2010.05.025_bib249","first-page":"341","article-title":"Comparison of the efficacy and acceptability of atypical antipsychotic drugs: a meta-analysis of randomized, placebo-controlled trials","volume":"82","author":"Srisurapanont","year":"1999","journal-title":"J. Med. Assoc. Thai."},{"key":"10.1016\/j.schres.2010.05.025_bib250","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1600-0447.2006.00947.x","article-title":"Negative symptoms of schizophrenia: a problem that will not go away","volume":"115","author":"Stahl","year":"2007","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2010.05.025_bib251","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1600-0447.2008.01334.x","article-title":"What comes first: atypical antipsychotics or the metabolic syndrome?","volume":"119","author":"Stahl","year":"2008","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2010.05.025_bib252","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.amjmed.2007.02.005","article-title":"Heterogeneity of treatment effects in schizophrenia","volume":"120","author":"Stroup","year":"2007","journal-title":"Am. J. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.schres.2010.05.025_bib253","first-page":"S70","article-title":"Blood dyscrasias induced by psychotropic drugs","volume":"37","author":"Stubner","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib254","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/ajp.2007.164.3.428","article-title":"Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study","volume":"164","author":"Swartz","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib255","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1176\/ajp.152.4.505","article-title":"Frontal leucotomy and related psychosurgical procedures in the era before antipsychotics (1935\u20131954): a historical review","volume":"152","author":"Swayze","year":"1995","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib256","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/schbul\/sbp080","article-title":"The evolution of cognitive behavior therapy for schizophrenia: current practice and recent developments","volume":"35","author":"Tai","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2010.05.025_bib257","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2174\/138161210790170102","article-title":"The application of PET technique for the development and evaluation of novel antipsychotics","volume":"16","author":"Takano","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.schres.2010.05.025_bib258","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/archpsyc.63.8.935","article-title":"Subjecting meta-analyses to closer scrutiny: little support for differential efficacy among second-generation antipsychotics. The author's reply","volume":"63","author":"Tandon","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib259","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/0006-3223(93)90242-6","article-title":"Covariance of positive and negative symptoms during neuroleptic treatment in schizophrenia: a replication","volume":"34","author":"Tandon","year":"1993","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib260","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0022-3956(93)90060-F","article-title":"Covariance of positive and negative symptoms during clozapine treatment in schizophrenia","volume":"27","author":"Tandon","year":"1993","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2010.05.025_bib261","first-page":"348","article-title":"Strategies for maximizing clinical effectiveness in the treatment of schizophrenia","volume":"12","author":"Tandon","year":"2006","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.schres.2010.05.025_bib262","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.schres.2008.01.022","article-title":"Schizophrenia, \u201cJust the Facts\u201d. What we know in 2008. Part 1: overview","volume":"100","author":"Tandon","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2010.05.025_bib263","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2008.04.011","article-title":"Schizophrenia, \u201cJust the Facts\u201d. What we know in 2008. Part 2: epidemiology and etiology","volume":"102","author":"Tandon","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2010.05.025_bib264","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.schres.2007.11.033","article-title":"World Psychiatry Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia","volume":"100","author":"Tandon","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2010.05.025_bib265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2009.03.005","article-title":"Schizophrenia, \u201cJust the Facts\u201d 4. Clinical features and conceptualization","volume":"110","author":"Tandon","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2010.05.025_bib266","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.brat.2004.06.020","article-title":"Is there evidence that cognitive behaviour therapy is an effective treatment for schizophrenia? A cautious or cautionary tale?","volume":"42","author":"Tarrier","year":"2004","journal-title":"Behav. Res. Ther."},{"key":"10.1016\/j.schres.2010.05.025_bib267","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1517\/14728222.11.9.1189","article-title":"Schizophrenia endophenotypes as treatment targets","volume":"11","author":"Thaker","year":"2007","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.schres.2010.05.025_bib268","series-title":"Cochrane Database Syst. Rev. CD000076","article-title":"Electroconvulsive therapy for schizophrenia","author":"Tharyan","year":"2005"},{"key":"10.1016\/j.schres.2010.05.025_bib269","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1600-0447.2008.01299.x","article-title":"Prospective comparison of course of disability in antipsychotic-treated and untreated schizophrenia patients","volume":"119","author":"Thirthalli","year":"2008","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2010.05.025_bib270","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1080\/15622970902718782","article-title":"Does catatonic schizophrenia improve faster with electroconvulsive therapy than other subtypes of schizophrenia ?","volume":"10","author":"Thirthalli","year":"2009","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib271","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4103\/0019-5545.58893","article-title":"Do antipsychotics limit disability in schizophrenia? A naturalistic comparative study in the community","volume":"52","author":"Thirthalli","year":"2010","journal-title":"Indian J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib272","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2165\/00023210-200923030-00002","article-title":"Management of patients presenting with acute psychotic episodes of schizophrenia","volume":"23","author":"Thomas","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2010.05.025_bib273","first-page":"2224","article-title":"Effectiveness of antipsychotic treatments in a nation-wide cohort of 2230 patients in community care after the first hospitalization due to schizophrenia and schizoaffective disorder","volume":"333","author":"Tiihonen","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.schres.2010.05.025_bib274","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","article-title":"11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)","volume":"374","author":"Tiihonen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2010.05.025_bib275","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.schres.2009.01.002","article-title":"\u201cThe efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis","volume":"109","author":"Tiihonen","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2010.05.025_bib324","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1517\/14728220903188438","article-title":"Histamine H3 and H4 receptors as novel drug targets","volume":"18","author":"Tiligada","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.schres.2010.05.025_bib276","series-title":"Cochrane Database of Systematic Reviews, CD000381","article-title":"Life skills programmes for chronic mental illnesses","author":"Tungpunkom","year":"2008"},{"key":"10.1016\/j.schres.2010.05.025_bib321","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1176\/foc.6.2.foc257","article-title":"Cognitive behavior therapy for schizophrenia","volume":"6","author":"Turkington","year":"2008","journal-title":"Focus"},{"key":"10.1016\/j.schres.2010.05.025_bib277","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/oxfordjournals.schbul.a007011","article-title":"A review of cognitive training in schizophrenia","volume":"29","author":"Twamley","year":"2003","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2010.05.025_bib278","first-page":"404","article-title":"The spurious advance of antipsychotic therapy","volume":"362","author":"Tyrer","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2010.05.025_bib279","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/schbul\/sbj071","article-title":"Cognitive rehabilitation for schizophrenia and the putative role of motivation and expectancies","volume":"32","author":"Velligan","year":"2006","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2010.05.025_bib280","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1021\/jm900521k","article-title":"Discovery of a new class of phosphodiesterase 10A inhibitors and identification of clinical candidate for the treatment of schizophrenia","volume":"52","author":"Verhoest","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.schres.2010.05.025_bib281","doi-asserted-by":"crossref","first-page":"801","DOI":"10.4088\/JCP.08m04391","article-title":"Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia","volume":"70","author":"Volpi","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib282","series-title":"Cochrane Database Syst. Rev. CD006391","article-title":"Benzodiazepines for schizophrenia","author":"Volz","year":"2007"},{"key":"10.1016\/j.schres.2010.05.025_bib283","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00213-003-1648-y","article-title":"Neuroleptic dysphoria: towards a new synthesis","volume":"171","author":"Voruganti","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2010.05.025_bib284","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1046\/j.1600-0447.2003.00269.x","article-title":"Delineating disability, labour force participation and employment restrictions among persons with psychosis","volume":"109","author":"Waghorn","year":"2004","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2010.05.025_bib285","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1176\/ajp.156.7.990","article-title":"Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials","volume":"156","author":"Wahlbeck","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib286","series-title":"Cochrane Database Systematic Reviews CD001951","article-title":"Haloperidol dose in the acute phase of schizophrenia","author":"Waraich","year":"2002"},{"key":"10.1016\/j.schres.2010.05.025_bib287","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00131746-200701000-00003","article-title":"EPS profiles: the atypical antipsychotics are not all the same","volume":"13","author":"Weiden","year":"2007","journal-title":"J. Psychiatr. Pract."},{"key":"10.1016\/j.schres.2010.05.025_bib288","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2009.05.018","article-title":"Influence of antipsychotics on mortality in schizophrenia: systematic review","volume":"113","author":"Weinmann","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2010.05.025_bib289","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1017\/S0033291703007645","article-title":"Antidepressants for the treatment of depression in schizophrenia: a systematic review","volume":"33","author":"Whitehead","year":"2003","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2010.05.025_bib290","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.pnpbp.2008.02.008","article-title":"Pharmacotherapy of schizophrenia with comorbid substance use disorder \u2014 reviewing the evidence and clinical recommendations","volume":"32","author":"Wobrock","year":"2008","journal-title":"Prog. Neuropsychopharm. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib291","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1055\/s-0030-1249097","article-title":"Combination therapy in the treatment of schizophrenia","volume":"43","author":"Wolff-Menzler","year":"2010","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib292","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1176\/ajp.148.6.714","article-title":"Benzodiazepines in the treatment of schizophrenia: a review and reappraisal","volume":"148","author":"Wolkowitz","year":"1991","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib293","series-title":"W.H.O. Model List of Essential Medicines","author":"World Health Organization","year":"2009"},{"key":"10.1016\/j.schres.2010.05.025_bib322","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/schbul\/17.2.325","article-title":"Neuroleptics and the natural course of schizophrenia","volume":"17","author":"Wyatt","year":"1991","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2010.05.025_bib294","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0920-9964(01)00242-0","article-title":"Rationale for the study of early intervention","volume":"51","author":"Wyatt","year":"2001","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2010.05.025_bib295","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0920-9964(88)90034-5","article-title":"Schizophrenia, just the facts. What do we know, how well do we know it?","volume":"1","author":"Wyatt","year":"1988","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2010.05.025_bib296","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/YCO.0b013e328322fbf4","article-title":"Cognitive remediation for schizophrenia: it is even more complicated","volume":"22","author":"Wykes","year":"2009","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib297","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/schbul\/sbm114","article-title":"Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor","volume":"34","author":"Wykes","year":"2008","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2010.05.025_bib298","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/sj.clpt.6100069","article-title":"Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study","volume":"81","author":"Yang","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.schres.2010.05.025_bib299","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejphar.2009.01.043","article-title":"Effects of TRK-820, a selective kappa opioid receptor agonist, on rat schizophrenia models","volume":"606","author":"Yoshikawa","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.schres.2010.05.025_bib300","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/09540260701797803","article-title":"The prevention of schizophrenia","volume":"19","author":"Yung","year":"2007","journal-title":"Int. Rev. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib301","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.psc.2009.12.001","article-title":"The promise and reality of pharmacogenetics in psychiatry","volume":"33","author":"Zandi","year":"2010","journal-title":"Psychiatr. Clin. N. Am."},{"key":"10.1016\/j.schres.2010.05.025_bib323","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/med.20130","article-title":"Dopamine D1 receptor ligands: where we are now and where are we going","volume":"29","author":"Zhang","year":"2009","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.schres.2010.05.025_bib302","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2005.02.018","article-title":"The effect of cognitive behavioral treatment on the positive symptoms of schizophrenia spectrum disorders: a meta-analysis","volume":"77","author":"Zimmermann","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2010.05.025_bib303","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/YCO.0b013e3283366427","article-title":"Polypharmacy in schizophrenia","volume":"23","author":"Zink","year":"2010","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.schres.2010.05.025_bib304","doi-asserted-by":"crossref","first-page":"562","DOI":"10.4088\/JCP.08m04261","article-title":"Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial","volume":"70","author":"Zisook","year":"2009","journal-title":"J. Clin. Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996410013460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996410013460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T09:19:26Z","timestamp":1740302366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996410013460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":320,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0920996410013460"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2010.05.025","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}